immunoadhesin
recombin
protein
combin
ligandbind
region
receptor
adhes
molecul
immunoglobulin
constant
domain
fdaapprov
immunoadhesin
design
modul
interact
human
receptor
normal
ligand
etanercept
enbrel
interfer
bind
tumour
necrosi
factor
tnf
tnfalpha
receptor
use
treat
inflammatori
diseas
rheumatoid
arthriti
like
antibodi
immunoadhesin
long
circul
halfliv
readili
purifi
affinitybas
method
avid
advantag
confer
bival
immunoadhesin
incorpor
normal
cellular
receptor
virus
bacteri
toxin
hold
great
yet
unreal
potenti
treat
infecti
diseas
decoy
receptor
immunoadhesin
potenti
advantag
pathogentarget
monoclon
antibodi
planet
biotechnolog
special
develop
antiinfect
immunoadhesin
use
plant
express
system
immunoadhesin
incorpor
cellular
receptor
anthrax
toxin
potent
block
toxin
activ
vitro
protect
anim
inhal
anthrax
immunoadhesin
base
receptor
human
rhinoviru
potent
block
infect
human
cell
one
major
caus
common
cold
immunoadhesin
target
mer
coronaviru
earli
stage
develop
describ
uniqu
challeng
involv
design
develop
immunoadhesin
target
infecti
diseas
hope
inspir
research
promis
class
drug
plant
offer
highli
attract
system
largescal
econom
product
vaccin
antibodi
therapeut
protein
much
work
planet
biotechnolog
focus
class
therapeut
recombin
protein
known
immunoadhesin
immunoadhesin
chimer
antibodylik
protein
combin
ligandbind
region
receptor
adhes
molecul
immunoglobulin
constant
domain
everi
immunoglobulin
fc
fusion
protein
consid
immunoadhesin
exampl
eftrenonacog
alfa
recombin
protein
factor
ix
blood
clot
factor
fuse
fc
achiev
extend
halflif
miguelino
powel
immunoadhesin
gener
intend
function
much
manner
mani
monoclon
antibodi
mab
bind
exquisit
specif
particular
ligand
block
interact
ligand
nativ
receptor
term
coin
describ
recombin
fusion
receptor
portion
immunoglobulin
g
capon
et
al
immunoadhesin
combin
extracellular
portion
human
tumour
necrosi
factoralpha
receptor
tnfr
human
hing
fc
region
first
develop
tnf
inhibitor
ashkenazi
et
al
peppel
et
al
eventu
given
name
etanercept
fda
approv
rheumatoid
arthriti
inflammatori
indic
trade
name
enbrel
highest
sell
biopharmaceut
least
last
year
fda
approv
five
immunoadhesin
design
interfer
human
receptorligand
interact
alefacept
strober
menon
abatacept
korhonen
moilanen
belatacept
larsen
et
al
rilonacept
receptor
accessori
protein
hoffman
et
al
aflibercept
vegf
receptor
holash
et
al
immunoadhesin
immunoglobulin
fc
fusion
protein
approv
develop
recent
comprehens
review
linderholm
chamow
b
immunoadhesin
three
critic
advantag
solubl
receptor
fragment
relat
halflif
affin
eas
purif
free
receptor
fragment
typic
short
live
circul
abil
fc
bind
neonat
fc
receptor
fcrn
impart
extend
circul
halflif
capon
et
al
kurschner
et
al
rath
et
al
weinblatt
et
al
immunoadhesin
bival
homodim
bival
result
increas
affin
avid
ligand
ashkenazi
chamow
final
bind
fc
protein
facilit
purif
addit
superior
solubl
receptor
immunoadhesin
underappreci
advantag
similarli
target
mab
low
immunogen
develop
antidrug
antibodi
ada
common
follow
repeat
dose
human
mab
patient
develop
substanti
ada
level
may
experi
loss
efficaci
typic
immun
respons
antiidiotyp
immun
respons
barteld
et
al
van
schouwenburg
et
al
immunoadhesin
elicit
lower
ada
titer
mab
ada
gener
nonneutr
van
schouwenburg
et
al
may
linker
region
connect
receptor
fc
often
foreign
part
molecul
none
fdaapprov
immunoadhesin
target
infecti
diseas
although
immunoadhesin
well
suit
purpos
mani
pathogen
virus
bacteri
toxin
gain
access
host
cell
bind
cell
surfac
receptor
immunoadhesin
deriv
host
receptor
potenti
effect
therapeut
possibl
advantag
antiinfect
mab
immunoadhesin
bind
virus
toxin
interfer
bind
host
receptor
via
fc
effector
function
promot
clearanc
target
viru
toxin
antigenpres
cell
jumpstart
activ
immun
respons
addit
decoy
molecul
toxin
viral
receptorbind
protein
immunoadhesin
may
less
vulner
develop
escap
mutant
monoclon
antibodi
reason
elabor
section
special
produc
antiinfect
immunoadhesin
plant
follow
section
describ
five
protein
develop
molecul
present
uniqu
challeng
relat
protein
design
develop
assay
quantif
biolog
activ
stabil
planta
purif
case
preclin
anim
test
protein
remain
promis
commerci
candid
other
encount
obstacl
preclud
develop
human
rhinovirus
major
caus
common
cold
common
cold
gener
thought
mild
diseas
signific
complic
result
cold
otiti
media
sinus
asthma
exacerb
common
human
rhinovirus
hrv
caus
adult
cold
cold
children
bella
rossmann
sperber
hayden
cost
societi
run
billion
dollar
per
year
character
hrv
serotyp
major
group
share
receptor
cell
surfac
glycoprotein
intercellular
adhes
greve
et
al
staunton
et
al
five
extracellular
immunoglobulinlik
domain
hydrophob
transmembran
domain
short
cytoplasm
domain
bind
site
hrv
locat
within
ntermin
domain
greve
et
al
staunton
et
al
express
mani
cell
import
immun
inflammatori
respons
well
respiratori
epitheli
cell
casasnova
et
al
recombin
solubl
form
consist
extracellular
domain
block
infect
human
cell
vitro
major
group
minor
group
hrv
serotyp
use
differ
receptor
crump
et
al
greve
et
al
marlin
et
al
ohlin
et
al
hrv
host
rang
restrict
higher
primat
chimpanze
effect
prevent
hrv
infect
coadminist
hrv
viru
administ
min
later
huguenel
et
al
human
clinic
trial
fund
boehring
ingelheim
pharmaceut
show
nasal
spray
reduc
sever
experiment
hrv
cold
result
advers
effect
evid
absorpt
nasal
mucosa
turner
et
al
also
inhibit
develop
serotypespecif
antihrv
antibodi
appear
boehring
ingelheim
abandon
develop
common
cold
therapeut
impract
dose
regimena
reduct
symptom
score
requir
daili
dose
mgday
daysand
cost
product
chines
hamster
ovari
cho
cell
earli
research
harvard
produc
seri
immunoadhesin
cho
cell
demonstr
least
order
magnitud
potent
monoval
neutral
hrv
vitro
martin
et
al
panel
nine
major
hrv
serotyp
immunoadhesin
time
potent
weight
basi
crump
et
al
result
suggest
immunoadhesin
potenti
becom
effect
therapi
cold
caus
hrv
howev
level
immunoadhesin
cell
cultur
supernat
lowless
mg
l
staunton
et
al
gener
construct
plant
express
immunoadhesin
compris
five
extracellular
domain
human
human
n
constant
region
chintalacharuvu
et
al
amino
acid
kdel
append
carboxyterminu
retain
protein
endoplasm
reticulum
enhanc
accumul
schouten
et
al
triguero
et
al
chose
n
allotyp
thought
less
suscept
proteolyt
cleavag
hing
region
senior
woof
gene
sequenc
synthes
use
codon
frequent
use
highli
express
tobacco
gene
incorpor
publish
strategi
codon
optim
angenon
et
al
chiapello
et
al
de
amici
marchetti
sawant
et
al
sawant
et
al
transcript
place
control
promot
deriv
binari
plasmid
vector
pbinplu
van
engelen
et
al
tobacco
nicotiana
tabacum
transform
use
agrobacterium
tumefacien
strain
hoekema
et
al
elit
line
contain
singl
transgen
insert
select
larg
number
plant
selfcross
produc
homozyg
line
plant
line
use
evalu
express
develop
purif
process
character
vitro
potenc
vivo
safeti
concentr
leav
plant
increas
nearli
linear
fashion
respect
time
seed
greenhous
flower
day
express
leav
reach
maximum
approxim
mgkg
fresh
weight
leav
figur
purif
transgen
tobacco
accomplish
tissu
extract
aqueou
buffer
follow
clarif
ultrafiltrationdiafiltr
gener
stabl
concentr
concentr
subject
threecolumn
purif
anion
exchang
chromatographi
remov
impur
captur
len
culinari
agglutinin
lca
affin
column
follow
elut
methyl
adglucopyranosid
final
polish
anion
exchang
chromatographi
chromatographi
follow
final
concentr
buffer
exchang
filtrat
frozen
storag
purif
yield
monomer
dimer
multimer
glycosyl
speci
figur
typic
final
yield
base
elisa
estim
crude
juic
abil
potenti
therapeut
inhibit
infect
hrv
vitro
measur
cytopath
effect
cpe
assay
andri
et
al
arruda
et
al
assay
hela
cell
express
expos
hrv
preincub
rang
inhibitor
concentr
day
extent
cell
kill
quantifi
use
dye
stain
live
cell
plantmad
compar
r
system
minneapoli
mn
standard
serotyp
assay
ec
valu
concentr
cytopath
effect
reduc
comput
figur
result
indic
six
time
potent
weight
basi
high
potenc
report
perhap
reflect
differ
hing
length
overal
molecular
geometri
furtado
et
al
dr
fred
hayden
cowork
univers
virginia
conduct
cellbas
toxic
test
plantmad
extens
cpe
assay
rang
hrv
serotyp
show
evid
toxic
three
human
cell
line
test
lgml
depend
cell
type
use
cpe
assay
time
potent
standard
hrv
serotyp
time
activ
clinic
hrv
isol
expect
inhibitori
effect
two
minor
group
hrv
serotyp
investig
effect
ntermin
amino
acid
choic
protein
stabil
planta
accumul
made
seven
new
ntermin
amino
acid
variant
addit
nativ
q
gln
nterminu
variant
includ
substitut
q
p
addit
l
v
g
lap
lapg
nterminu
variant
express
transient
n
tabacum
ex
vivo
protein
halflif
variant
measur
presenc
cycloheximid
geyer
et
al
variant
v
lapg
nterminu
longest
halfliv
approxim
wildtyp
variant
halflif
approxim
wildtyp
protein
higher
planta
stabil
lapg
variant
led
higher
accumul
stabl
transgen
n
tabacum
plant
highest
express
lapg
line
level
higher
highest
express
nativ
line
gener
time
howev
addit
lapg
nterminu
result
approxim
reduct
potenc
determin
cpe
assay
figur
nasal
dose
studi
rat
sought
identifi
acut
toxic
determin
whether
toxic
revers
dosag
volum
concentr
chosen
base
success
studi
human
safeti
efficaci
hrv
infect
turner
et
al
studi
deliv
volum
per
nasal
passag
surfac
area
llcm
applic
h
mole
rat
human
rat
observ
min
dose
sign
distress
none
note
macroscop
histopatholog
examin
respiratori
tissu
identifi
minimaltomild
acut
inflamm
anterior
turbin
nare
anim
sacrif
h
last
dose
dose
depend
deliveri
pipett
suspect
caus
rat
nostril
close
anaesthesia
open
pipett
dose
irrit
present
anim
sacrif
day
detect
serum
either
sacrific
time
limit
detect
elisa
ngml
less
deliv
nose
present
serum
either
sampl
time
similar
multidos
studi
rabbit
confirm
deliveri
pipett
could
caus
irrit
drip
administr
test
articlerel
observ
note
upon
macroscop
histopatholog
examin
rabbit
respiratori
tissu
min
ad
adher
cell
cell
well
plate
cell
incub
h
stain
viabil
crystal
violet
percentag
cpe
inhibit
calcul
rel
cell
expos
viru
alon
mean
ae
standard
deviat
three
well
per
dilut
shown
thu
appear
caus
littl
acut
toxic
rat
rabbit
absenc
toxic
preliminari
studi
along
vitro
viru
neutral
data
indic
warrant
develop
anthrax
still
threat
public
health
bacillu
anthraci
soilborn
anaerob
spore
form
bacterium
caus
multipl
patholog
man
hick
et
al
joshi
et
al
low
glomski
sweeney
et
al
inhal
b
anthraci
endospor
initi
acut
sever
system
bacteri
infect
inhal
anthrax
unless
treat
immedi
aggress
antibiot
therapi
essenti
fatal
limit
effect
antibiot
symptomat
patient
like
causal
agent
b
anthraci
elabor
two
toxin
lethal
toxin
letx
edema
toxin
edtx
continu
damag
tissu
even
bacterium
dead
protect
antigen
pa
common
compon
letx
edtx
bind
host
cell
surfac
receptor
facilit
uptak
toxic
protein
lethal
factor
edema
factor
liu
et
al
rainey
et
al
scobi
young
scobi
et
al
follow
anthrax
attack
borio
et
al
jernigan
et
al
william
et
al
sever
compani
initi
program
develop
antipa
monoclon
antibodi
mab
treatment
inhal
anthrax
mab
either
prevent
pa
bind
cellular
receptor
interfer
pa
abil
facilit
toxin
entri
cell
death
leysath
et
al
liu
et
al
migon
et
al
moham
et
al
peterson
et
al
peterson
et
al
subramanian
et
al
vital
et
al
pa
bind
two
relat
cell
surfac
protein
tumor
endotheli
marker
capillari
morphogenesi
protein
major
receptor
mediat
lethal
vivo
bank
et
al
bradley
et
al
liu
et
al
scobi
et
al
affin
pa
quit
high
pm
depend
measur
method
use
liu
et
al
wigelsworth
et
al
solubl
version
extracellular
domain
inhibit
intox
human
anim
cell
premix
pa
scobi
et
al
suggest
immunoadhesin
could
viabl
altern
antipa
antibodi
challeng
immunoadhesin
design
illustr
earli
attempt
produc
stabl
function
immunoadhesin
first
design
use
amino
acid
human
fuse
three
constant
domain
human
construct
begin
amino
acid
signal
peptid
murin
immunoglobulin
light
chain
choic
fragment
base
sequenc
solubl
previous
shown
inhibit
letx
vitro
scobi
et
al
use
three
heavi
chain
constant
domain
work
well
immunoadhesin
open
read
frame
clone
binari
vector
transform
tumefacien
use
transient
express
nicotiana
benthamiana
use
vacuumassist
wholepl
infiltr
method
kapila
et
al
vaquero
et
al
express
immunoadhesin
purifi
protein
chromatographi
visual
coomassiestain
sdspage
predict
monomer
molecular
weight
origin
construct
kda
reduc
sampl
minor
fraction
purifi
protein
kda
band
major
protein
three
smaller
band
kda
figur
lane
band
visual
coomassi
blue
also
react
antihuman
igg
western
blot
analysi
shown
ntermin
sequenc
smaller
fragment
reveal
began
amino
acid
sequenc
middl
first
constant
domain
suggest
presenc
proteolyt
sensit
site
examin
extracellular
domain
crystal
structur
santelli
et
al
suggest
amino
acid
origin
aa
necessari
structur
domain
pa
bind
function
made
three
new
variant
without
aa
without
domain
without
either
lack
signific
fraction
degrad
protein
fragment
figur
lane
variant
use
develop
modifi
introduct
mutat
fc
region
make
nonglycosyl
variant
neither
vitro
potenc
measur
standard
cellbas
lethal
toxin
neutral
assay
vivo
potenc
measur
b
anthraci
spore
challeng
studi
rabbit
significantli
affect
presenc
absenc
nglycosyl
wycoff
et
al
follow
earli
studi
aglycosyl
form
develop
aglycosyl
ptrakc
plant
express
vector
schinkel
et
al
tumefacien
english
et
al
use
transform
n
tabacum
transgen
n
tabacum
plant
bred
gener
matur
accumul
approxim
mgkg
fresh
weight
time
higher
level
report
andrianov
et
al
construct
incorpor
slightli
smaller
portion
lack
two
cystein
particip
disulphid
bond
nativ
protein
also
less
potent
vitro
one
produc
suggest
specif
design
immunoadhesin
crucial
determin
express
biolog
activ
cellbas
toxin
neutral
assay
tna
potenc
anthrax
antitoxin
express
ec
concentr
antitoxin
reduc
cytotox
li
et
al
ec
ngml
similar
report
ec
antipa
antibodi
raxibacumab
zhang
et
al
anthim
tm
moham
et
al
sawadahirai
et
al
demonstr
efficaci
inhal
anthrax
rabbit
cynomolgu
macaqu
model
postexposur
prophylaxi
studi
rabbit
challeng
nasal
instil
ld
b
anthraci
ame
spore
administ
intraven
within
hour
spore
challeng
dose
mg
bodi
weight
effect
prevent
death
survivor
dose
mg
result
surviv
survivor
dose
survivor
rechalleng
b
anthraci
ame
spore
month
first
challeng
expect
complet
absent
circul
four
anim
surviv
studi
provid
proof
concept
postinfect
therapeut
indic
wycoff
et
al
triggertotreat
studi
twentyon
rabbit
given
aerosol
challeng
ld
treat
follow
signific
increas
bodi
temperatur
sibt
anim
confirm
bacterem
toxem
treatment
fiftyseven
per
cent
anim
treat
mgkg
surviv
anim
treat
mgkg
anim
treat
mgkg
surviv
figur
untreat
anim
succumb
diseas
onesid
fisher
exact
test
reveal
significantli
higher
surviv
rate
group
receiv
mgkg
p
mgkg
p
antitoxin
compar
untreat
control
group
two
studi
cynomolgu
macaqu
demonstr
efficaci
inhal
anthrax
postexposur
prophylaxi
studi
cynomolgu
macaqu
challeng
ld
b
anthraci
ame
spore
via
small
particl
aerosol
administ
intraven
min
challeng
dose
mgkg
protect
three
four
anim
receiv
drug
surviv
eight
untreat
anim
die
p
dose
mgkg
anim
surviv
result
significantli
differ
untreat
control
trigger
treat
studi
twentyfour
cynomolgu
macaqu
challeng
ld
b
anthraci
ame
spore
via
small
particl
aerosol
seventeen
administ
mgkg
intraven
pa
detect
serum
h
challeng
six
anim
treat
six
untreat
control
anim
succumb
diseas
anim
receiv
treatment
confirm
posit
blood
cultur
prior
receiv
treatment
confirm
posit
anim
ten
surviv
figur
onesid
fisher
exact
test
reveal
significantli
higher
surviv
rate
treat
confirm
blood
cultureposit
group
compar
untreat
control
group
p
publish
report
indic
antipa
mab
equal
effect
vivo
inhal
anthrax
report
surviv
follow
dose
mgkg
triggertotreat
nonhuman
primat
model
malkevich
et
al
migon
et
al
riddl
et
al
far
evid
suggest
antipa
mab
inhibit
toxic
anthrax
lethal
toxin
similar
mechan
bind
high
affin
pa
type
molecul
prevent
pa
carri
normal
function
one
way
immunoadhesinlik
may
superior
mab
bind
toxin
differ
suscept
two
molecul
deliber
modif
target
possibl
engin
pa
elimin
epitop
particular
mab
without
affect
pa
abil
bind
cell
surfac
contrast
chang
pa
reduc
bind
also
reduc
pa
bind
cell
surfac
thu
toxic
exampl
amino
acid
substitut
four
residu
pa
elimin
bind
thu
neutral
antipa
mab
precursor
anthim
tm
without
greatli
reduc
vitro
toxic
letx
contain
mutant
pa
rosovitz
et
al
contrast
fulli
effect
neutral
letx
contain
mutat
wycoff
et
al
pharmacokinet
studi
rabbit
show
elimin
fit
best
twocompart
model
termin
halflif
studi
cynomolgu
macaqu
evalu
pharmacokinet
deliv
intraven
iv
intramuscularli
im
calcul
termin
iv
im
halfliv
h
respect
valu
similar
human
mab
speci
deng
et
al
deng
et
al
pilot
repeatdos
toxicolog
studi
rat
cynomolgu
macaqu
found
dosag
mgkg
welltoler
test
articlerel
mortal
chang
clinic
observ
food
consumpt
bodi
weight
urinalysi
paramet
gross
necropsi
find
organ
weight
occur
overal
test
articlerel
advers
find
identifi
studi
although
anim
develop
antibodi
human
fc
antidrug
antibodi
human
detect
pilotscal
purif
transgen
n
tabacum
develop
pilotscal
manufactur
process
use
suppli
highqual
product
anim
efficaci
preclin
safeti
test
goal
prepar
drug
product
suitabl
test
human
use
good
manufactur
practic
gmp
manufactur
use
gmp
mean
purifi
plant
biomass
prepar
releas
drug
product
use
test
judg
attribut
ident
potenc
puriti
strength
stabil
appear
safeti
eg
endotoxin
aggreg
alkaloid
host
antigen
etc
activ
must
reliabl
reproduc
document
show
materi
procedur
specifi
accept
purpos
properli
use
perform
scale
product
g
per
lot
establish
procedur
obtain
expect
qualiti
attribut
behavior
intermedi
product
effort
includ
creation
qualiti
system
infrastructur
compris
manufactur
make
drug
product
facil
maintain
manufactur
environ
qualiti
control
test
attribut
raw
materi
environ
purif
qualiti
assur
coordin
review
manufacturingassoci
action
flow
chart
pilotscal
manufactur
figur
show
upstream
process
specif
obtain
raw
protein
plant
biomass
downstream
process
similar
biopharmaceut
purif
varieti
sourc
involv
chromatographi
formul
fill
oper
except
freez
occur
room
temperatur
typic
pilotscal
manufactur
run
n
tabacum
plant
transgen
grown
matur
greenhous
kg
stem
leav
harvest
approxim
sq
ft
rais
bed
approxim
day
seed
accumul
mgkg
plant
biomass
biomass
store
overnight
bin
next
day
biomass
pulp
use
grinder
reitzbepex
stackedblad
disintegr
squeez
screw
press
vincent
buffer
produc
approxim
l
juic
figur
green
opaqu
larg
free
cellulos
solid
juic
treat
agglomer
solid
briefli
reduc
ph
return
ph
result
loss
found
juic
found
brief
acidif
necessari
produc
follow
centrifug
clarifi
juic
amen
chromatographi
continu
centrifug
use
alfa
laval
clara
stackeddisc
clarifi
remov
total
protein
agglomer
solid
initi
present
vv
bioburden
significantli
reduc
clarif
filtrat
lm
lm
reduc
bioburden
less
cfuml
without
loss
diafilt
concentr
prepar
use
kda
mwco
cassett
reduc
volum
step
yield
phenol
diafilt
concentr
subject
proprietari
precipit
remov
signific
amount
protein
color
nucleic
acid
final
filtrat
frozen
storag
point
specif
activ
increas
volum
reduc
phenol
reduc
overal
yield
product
g
kg
biomass
downstream
process
combin
filter
supernat
protein
chromatographi
prepar
g
lot
drug
product
polish
cation
exchang
chromatographi
reduc
endotoxin
aggreg
accept
level
eumg
aggreg
sechplc
figur
step
yield
protein
chromatographi
step
yield
cation
exchang
chromatographi
drug
substanc
concentr
bufferexchang
phosphatebuff
salin
fill
final
contain
overal
yield
product
scale
puriti
drug
product
prepar
mgml
depend
upon
studi
store
frozen
largest
task
remain
develop
pilotscal
manufactur
increas
puriti
reduc
nucleic
acid
host
antigen
content
improv
step
yield
mitig
product
loss
accompani
introduct
addit
polish
step
like
includ
anion
exchang
chromatographi
plan
replac
acidbas
titrat
agglomer
juic
solid
addit
proprietari
precipit
subsequ
clarif
excel
product
recoveri
nearli
wide
believ
recombin
protein
product
plant
econom
mammalian
cell
cultur
product
public
describ
rigor
cost
analys
limit
buyel
fischer
kaufman
kalaitzandonak
tuse
et
al
kaufman
kalaitzandonak
estim
final
per
unit
cost
mab
corn
express
seed
mg
mabkg
seed
much
mab
produc
use
mammalian
cell
cultur
system
assum
gl
cost
model
use
paper
indic
increas
mab
express
result
substanti
reduct
product
purif
cost
protein
express
plant
improv
optim
codon
usag
reflect
frequent
use
codon
express
host
batard
et
al
horvath
et
al
huang
et
al
joensuu
et
al
kang
et
al
b
rouwend
et
al
suo
et
al
gener
codon
optim
strategi
synonym
codon
mutat
concern
increas
translat
rate
ikemura
kane
pay
littl
attent
possibl
affect
transcript
mrna
stabil
howev
public
shown
codon
usag
dramat
affect
mrna
level
kudla
et
al
kudla
et
al
nguyen
et
al
tokuoka
et
al
effort
improv
antibodi
express
compar
number
synonym
codon
variant
human
heavi
chain
use
transient
agroinfiltr
n
benthamiana
n
tabacum
combin
variant
kappa
chain
codon
variant
gener
signific
differ
protein
accumul
surprisingli
mrna
level
produc
gene
variant
consider
differ
despit
use
promot
upstream
downstream
utr
express
construct
interestingli
found
gener
invers
associ
protein
express
level
codon
adapt
index
cai
although
gene
test
rel
high
cai
henc
gene
featur
like
outweigh
cai
impact
express
found
best
correl
mrna
protein
accumul
comput
predict
mrna
thermost
fold
minimum
gibb
free
energi
high
mrna
thermost
low
gibb
free
energi
lead
high
mrna
protein
level
surpris
find
research
often
tri
prevent
strong
mrna
secondari
structur
assum
structur
imped
progress
ribosom
postul
thermodynam
stabl
mrna
secondari
structur
play
key
role
facilit
high
protein
accumul
plant
could
effect
approach
improv
product
biotherapeut
plant
call
best
express
synonym
codon
variant
rnaoptim
fc
sequenc
compar
express
two
gene
construct
one
contain
n
tabacum
codonoptim
fc
sequenc
gener
commonli
use
onlin
algorithm
incorpor
rnaoptim
fc
sequenc
two
gene
cai
gc
content
codonoptim
rnaoptim
sequenc
respect
tumefaciensmedi
transient
express
n
tabacum
n
benthamiana
leav
observ
least
higher
protein
accumul
use
rnaoptim
fc
sequenc
figur
also
gener
stabl
transgen
tobacco
plant
n
tabacum
cultivar
wisconsin
tumefaciensmedi
transform
two
gene
variant
describ
rnaoptim
gene
variant
express
higher
level
mgkg
produc
larger
number
detect
transform
codonoptim
counterpart
figur
produc
immunoadhesin
vacuumassist
agroinfiltr
n
benthamiana
routin
coinfiltr
tumefacien
strain
design
introduc
viral
suppressor
posttranscript
gene
silenc
ptg
garabagi
et
al
voinnet
et
al
arzola
et
al
evalu
coexpress
one
construct
nine
differ
ptg
suppressor
protein
result
greatest
enhanc
express
day
postinfiltr
tenfold
higher
compar
absenc
ptg
suppress
current
three
biolog
licens
treatment
inhal
anthrax
antipa
mab
raxibacumab
gsk
anthim
elusi
therapeut
pine
brook
nj
human
serumderiv
anthrasil
emerg
biosolut
gaithersburg
md
drug
approv
fda
socal
anim
rule
provid
framework
demonstr
safeti
efficaci
drug
ethic
test
efficaci
human
depart
health
human
servic
demonstr
efficaci
plantproduc
inhal
anthrax
rabbit
cynomolgu
macaqu
demonstr
safeti
repeat
dose
high
mgkg
pilot
rat
cynomolgu
macaqu
studi
current
seek
fund
inden
anim
toxicolog
studi
requir
phase
clinic
trial
middl
east
respiratori
syndrom
mer
caus
mer
coronaviru
merscov
newli
emerg
human
health
threat
estim
case
fatal
rate
majumd
et
al
merscov
close
relat
bat
coronavirus
lead
earli
specul
bat
might
sourc
human
infect
cui
et
al
ithet
et
al
lau
et
al
recent
studi
found
merscov
widespread
dromedari
camel
abdelmoneim
alexandersen
et
al
ferguson
van
kerkhov
haagman
et
al
meyer
et
al
viru
circul
camel
sinc
least
alagaili
et
al
seem
fairli
clear
camel
origin
mani
human
infect
azhar
et
al
kupferschmidt
memish
et
al
current
effect
therapi
viru
like
coronavirus
merscov
virion
use
larg
surfac
spike
glycoprotein
interact
entri
target
cell
glycoprotein
consist
ntermin
subunit
contain
receptorbind
domain
rbd
follow
membraneproxim
domain
transmembran
domain
ctermin
intracellular
domain
qian
et
al
copurif
merscov
domain
raj
colleagu
determin
dipeptidyl
peptidas
function
merscov
cellular
receptor
express
surfac
sever
cell
type
includ
found
human
airway
support
role
merscov
receptor
polyclon
antiserum
direct
inhibit
merscov
infect
human
bronchial
epitheli
cell
human
cell
solubl
inhibit
vero
cell
infect
merscov
nonsuscept
cell
transform
express
cell
surfac
human
becam
suscept
infect
serin
proteas
enzymat
function
appear
essenti
viral
entri
cleav
peptid
bond
releas
prolinecontain
dipeptid
nterminu
physiolog
import
polypeptid
hopsuhavu
glenner
propos
import
regul
differ
physiolog
pathophysiolog
condit
bengsch
et
al
mentlein
miyazaki
et
al
moran
et
al
shigeta
et
al
addit
cell
surfac
form
solubl
ident
amino
acid
extracellular
domain
found
serum
lgml
extracellular
domain
consist
ntermin
eightblad
bpropel
domain
ctermin
ab
hydrolas
domain
merscov
protein
receptorbind
domain
rbd
contact
bpropel
domain
contact
hydrolas
domain
sever
potenti
merscov
therapi
report
includ
small
molecul
hart
et
al
lu
et
al
mab
either
ohnuma
et
al
merscov
rbd
block
infect
vitro
jiang
et
al
ying
et
al
mab
approach
howev
potenti
drawback
target
widespread
human
cell
surfac
antigen
antibodi
could
pleiotrop
effect
patient
mab
viru
rbd
may
effect
develop
neutral
escap
mutant
real
possibl
seen
antisar
mab
ng
et
al
rockx
et
al
alaninescan
mutat
rbd
merscov
pseudovirus
littl
effect
infect
viru
significantli
reduc
inhibitori
effect
even
potent
mab
pseudoviru
entri
jiang
et
al
evid
variabl
rbd
sequenc
natur
merscov
isol
may
origin
select
pressur
neutral
antibodi
vivo
tang
et
al
pursu
immunoadhesin
approach
develop
merscov
therapeut
sequenc
encod
human
extracellular
domain
aa
bpropel
domain
either
aa
pcramplifi
human
clone
clone
plant
binari
vector
ptrakc
upstream
infram
rnaoptim
fc
sequenc
human
iga
construct
truncat
remov
acid
ctermin
iga
tail
piec
sequenc
enabl
dimer
iga
format
significantli
reduc
iga
express
plant
hadlington
et
al
requir
bind
fc
alpha
receptor
brunk
et
al
construct
includ
ctermin
kdel
peptid
express
vector
introduc
tumefacien
maclean
et
al
transient
express
whole
n
benthamiana
plant
initi
vacuuminfiltr
recombin
agrobacterium
fusion
purifi
plant
homogen
use
protein
chromatographi
igg
fc
fusion
captureselect
iga
affin
matrix
life
technolog
carlsbad
ca
iga
fc
fusion
express
level
rang
mg
fresh
plant
weight
number
high
unexpect
nucleotid
sequenc
human
codonor
rnaoptim
plant
protein
analys
sdspage
figur
b
size
exclus
chromatographi
figur
major
expect
dimer
form
nonreduc
condit
monomer
form
reduc
puriti
estim
scan
gel
band
intens
use
biorad
gel
doc
ez
imag
igg
fc
fusion
pure
iga
fc
fusion
pure
fusion
entir
extracellular
domain
amino
acid
fc
design
fc
bound
domain
recombin
spike
protein
elisa
ec
lgml
enhanc
compar
solubl
ec
lgml
smaller
fc
fusion
bpropel
domain
fc
bind
well
ec
lgml
structur
analysi
engel
et
al
suggest
ntermin
extens
blade
tighten
propel
structur
interact
immedi
ctermin
extens
blade
viii
produc
third
fusion
fc
test
well
found
also
bound
poorli
figur
elisa
result
suggest
fusion
extracellular
domain
fc
bind
somewhat
better
merscov
similar
fusion
work
underway
test
neutral
potenc
immunoadhesin
vitro
vsvbase
pseudoviru
du
et
al
live
merscov
anticip
unlik
mab
subject
viru
select
neutral
escap
mutant
mutat
decreas
bind
like
decreas
bind
nativ
receptor
result
attenu
viru
erythrocyt
invas
merozoit
form
plasmodium
falciparum
essenti
pathogenesi
malaria
crosnier
et
al
show
erythrocyt
antigen
basigin
bsg
receptor
parasit
ligand
essenti
blood
stage
growth
erythrocyt
invas
could
inhibit
solubl
pentamer
basigin
basigin
knockdown
antibasigin
antibodi
posit
basigin
immunoadhesin
might
use
malariaprevent
agent
travel
malariaendem
region
set
produc
test
basiginfc
plant
dna
sequenc
human
basigin
extracellular
domain
amino
acid
genbank
access
isoform
codon
optim
express
n
tabacum
mutat
prevent
glycosyl
three
potenti
nlink
glycosyl
site
perform
crosnier
fc
sequenc
human
clone
frame
downstream
bsg
sequenc
ptrakc
plant
express
vector
maclean
et
al
express
vector
introduc
tumefacien
express
n
benthamiana
plant
accomplish
basiginfc
purifi
plant
extract
protein
chromatographi
puriti
assembl
dimer
character
sdspage
approxim
lg
basiginfc
per
gram
fresh
weight
elut
protein
column
satur
repres
minimum
estim
level
accumul
plant
basiginfc
bound
recombin
gift
g
wright
wellcom
trust
sanger
institut
elisa
figur
protein
abl
inhibit
parasit
growth
standard
vitro
assay
hui
et
al
concentr
lg
ml
probabl
dimer
basiginfc
avid
pentamer
form
test
crosnier
well
practic
dose
human
administr
project
discontinu
hantavirus
health
threat
hantavirus
famili
bunyavirida
emerg
zoonot
virus
harbor
small
mammal
caus
febril
diseas
human
new
world
hantavirus
respons
hantaviru
cardiopulmonari
syndrom
hcp
america
syndrom
result
respiratori
failur
cardiogen
shock
subsequ
death
case
sin
nombr
viru
snv
prototyp
new
world
hantaviru
caus
vast
major
hcp
case
unit
state
kanerva
et
al
mertz
et
al
zaki
et
al
approv
antivir
therapi
hcp
decayacceler
factor
daf
one
cell
surfac
protein
postul
mediat
least
vitro
hantaviru
entri
cultur
cell
yet
direct
role
viru
entri
well
understood
nevertheless
pretreat
cell
antidaf
antibodi
recombin
human
daf
mous
cell
rhdaf
result
inhibit
hantaviru
infect
krautkram
zeier
popugaeva
et
al
daf
express
high
level
lumin
surfac
endotheli
cell
subvert
mani
bacteri
viral
pathogen
includ
echovirus
bergelson
et
al
ward
et
al
human
enterovirus
powel
et
al
abil
variant
bind
protein
merscov
test
use
ligandbind
elisa
dilut
variant
solubl
ad
protein
coat
microtit
plate
bound
detect
use
goat
igg
report
donkey
antigoat
igg
label
hrp
base
forgo
evid
ration
decoy
receptor
base
daf
might
act
broad
spectrum
therapeut
hantaviru
infect
multival
bind
avid
hantaviru
particl
cellular
daf
receptor
high
kda
pm
buranda
et
al
bival
daffc
might
expect
bind
viru
particl
affin
much
greater
monomer
rhdaf
one
challeng
design
daf
immunoadhesin
presenc
nlink
glycosyl
site
daf
protein
role
nglycan
bind
hantaviru
known
effect
differ
nglycan
structur
result
plant
express
could
predict
thu
made
three
glycosyl
variant
base
prototyp
daffc
construct
aa
human
daf
hing
fc
human
aglycosyl
variant
includ
follow
complex
daffc
complextyp
nglycan
daf
plantspecif
residu
ii
high
mannos
daffc
ctermin
sekdel
result
high
mannosetyp
nglycan
daf
iii
aglycosyl
daffc
glycosyl
site
daf
abolish
chang
asn
residu
gln
three
daffc
variant
express
high
level
n
benthamiana
mg
proteinkg
leav
bound
elisa
recombin
human
figur
receptor
cellular
daf
hamann
et
al
significantli
better
rhdaf
howev
monomer
rhdaf
abl
inhibit
bind
fluoresc
label
snv
cultur
tanou
b
cell
higher
molar
concentr
plantmad
daffc
reduc
viru
bind
figur
buranda
et
al
reason
unclear
differ
daffc
glycoform
glycoform
rhdaf
possibl
specif
natur
daf
nglycan
import
bind
viru
bind
also
possibl
daffc
fusion
perhap
steric
unfavour
hantaviru
bind
unlik
solubl
rhdaf
addit
engin
may
need
gener
fulli
function
daf
immunoadhesin
antiinfect
immunoadhesin
principl
use
infecti
diseas
known
cellular
receptor
despit
none
achiev
fda
approv
purpos
potenti
protein
antiinfect
agent
therefor
fulli
exploit
immunoadhesin
may
particularli
use
pathogen
high
mutat
rate
multipl
pathogen
share
cellular
receptor
also
immunoadhesin
develop
emerg
diseas
soon
receptor
elucid
import
design
consider
whether
use
full
partial
receptor
whether
mutat
receptor
improv
bind
affin
well
linker
choic
fc
isotyp
choic
review
other
experi
produc
antivir
antitoxin
immunoadhesin
plant
plant
certain
advantag
express
system
product
immunoadhesin
easili
made
bacteri
express
system
complex
requir
intraand
interchain
disulphid
bond
act
primarili
receptor
antagonist
high
immunoadhesin
concentr
may
need
achiev
biolog
effect
depend
receptor
affin
biolog
ligand
concentr
case
high
immunoadhesin
dose
requir
econom
plant
product
becom
import
challeng
involv
develop
success
antiinfect
immunoadhesin
may
somewhat
greater
similarli
target
monoclon
antibodi
found
initi
design
need
modifi
achiev
stabl
function
protein
first
immunoadhesin
exhibit
great
promis
hiv
therapeut
year
ago
base
vitro
data
disappoint
clinic
fletcher
et
al
schooley
et
al
howev
recent
publish
work
show
judici
protein
engin
improv
stabil
solubl
potenc
six
copi
engin
singl
domain
two
copi
antibodi
domain
target
coreceptorbind
site
fuse
kappa
constant
region
result
hexaval
immunoadhesin
time
potent
clinic
test
vitro
neutral
much
broader
rang
isol
includ
sever
neutral
broadli
neutral
monoclon
antibodi
chen
et
al
concern
rais
paper
author
rel
complex
structur
fusion
protein
might
pose
potenti
challeng
largescal
product
perhap
express
plant
consid
addit
support
inform
may
found
onlin
version
articl
figur
increas
accumul
time
greenhousegrown
plant
figur
inhibit
cytopath
effect
cpe
figur
character
lot
size
exclus
hplc
stain
free
sdspage
figur
plantmad
basiginfc
bind
recombin
elisa
figur
bind
activ
plantmad
daffc
variant
rhdaf
function
elisa
figur
rhdaf
better
plantmad
daffc
variant
block
bind
fluoresc
label
hantaviru
particl
inactiv
sin
nombr
viru
snv
tanou
b
cell
